Advertisement

The NINDS t-PA Stroke Trial: Progress Report

  • The NINDS t-PA Stroke Trial Investigators
Conference paper

Abstract

Effective treatment to improve outcome after the onset of acute ischemic stroke continues to be elusive. Interest in thrombolytic therapy as a potential treatment for stroke has undergone a revival coincident with the development of newer agents, such as human recombinant tissue-type plasminogen activator (rt-PA), and better appreciation for the need for rapid treatment within the first minutes to hours after the onset of symptoms [1].

Keywords

Acute Ischemic Stroke Thrombolytic Therapy Stroke Onset Data Monitoring Committee Stroke Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Levine SR, Brott TG (1992) Thrombolytic therapy in cerebrovascular disorders. Prog Cardiovasc Dis 34: 235–262PubMedCrossRefGoogle Scholar
  2. 2.
    del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R Jr, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM (1992) Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 32: 78–86PubMedCrossRefGoogle Scholar
  3. 3.
    Brott TG, Haley EC, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marier JR (1992) Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23: 632–640PubMedCrossRefGoogle Scholar
  4. 4.
    Haley EC, Levy DE, Brott TG, Sheppard GL, Wong MCW, Kongable GL, Torner JC, Marler JR (1992) Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 23: 641–645PubMedCrossRefGoogle Scholar
  5. 5.
    Von Kummer R, Hacke W (1992) Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 23: 646–652CrossRefGoogle Scholar
  6. 6.
    Mori E, Yoneda Y, Tabuchi M. Yoshida T, Ohkawa S. Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A (1992) Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 42: 976–982Google Scholar
  7. 7.
    Haley EC, Brott TG, Sheppard GL, Barsan W. Broderick J, Marler JR, Kongable GL, Spilker J, Massey S, Hansen CA, Torner JC, for the TPA Bridging Study Group (1993) Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 24: 1000–1004PubMedCrossRefGoogle Scholar
  8. 8.
    Brott TG, Adams HP. Olinger CP. Marler JR, Barsan WG. Biller J, Spilker J, Holleran R. Eberle R, Hertzberg V. Rorick M, Moomaw CJ, Walker M (1989) Measurement of acute cerebral infarction: a clinical examination scale. Stroke 20: 864–870PubMedCrossRefGoogle Scholar
  9. 9.
    Lefkopoulou M. Ryan L (1989) Global tests for multiple binary outcomes. Biometrics 4: 975–988Google Scholar

Copyright information

© Springer-Verlag Tokyo 1995

Authors and Affiliations

  • The NINDS t-PA Stroke Trial Investigators

There are no affiliations available

Personalised recommendations